文献速递血栓与止血

治疗剂量的重组凝血因子VIIa在血友病中通过血小板依赖性和非依赖性机制生成凝血酶

Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
PubMed 文献 · J Thromb Haemost · 2020-06-25

研究在获得性和遗传性血友病小鼠中清除血小板后,用抗血小板抗体处理并制造隐静脉损伤,评估药理学浓度重组凝血因子VIIa(rFVIIa)在损伤部位的凝血酶生成。结果显示rFVIIa在血小板清除的血友病小鼠中仍能生成大量凝血酶,且FVIII-/-、EPCR缺陷FVIII-/-和EPCR过表达FVIII-/-小鼠间无差异,血小板未检测到EPCR表达,提示rFVIIa通过血小板依赖和非依赖两种机制生成凝血酶。

要点

  • 抗小鼠CD42抗体使小鼠血小板清除超过95%。
  • 药理学剂量rFVIIa在血小板清除的血友病小鼠中仍生成大量凝血酶。
  • FVIII-/-、EPCR缺陷FVIII-/-和EPCR过表达FVIII-/-小鼠间凝血酶生成无差异。

核心结论

  • 药理学浓度的rFVIIa在血友病中通过血小板依赖性和血小板非依赖性两种机制生成凝血酶。

研究设计与样本

  • 在获得性和遗传性血友病小鼠中使用抗血小板抗体清除血小板,进行隐静脉损伤,通过测量损伤部位凝血酶生成评估药理学浓度rFVIIa的止血效果。

主要发现

  • 给予抗小鼠CD42抗体使小鼠血小板清除超过95%。
  • 与野生型小鼠相比,血友病小鼠在损伤部位仅生成小部分凝血酶。
  • 血友病小鼠清除血小板后凝血酶生成进一步减少。
  • 给予药理学剂量rFVIIa后,即使血小板清除的血友病小鼠也生成大量凝血酶。
  • 在清除或未清除血小板的FVIII-/-、EPCR缺陷FVIII-/-和EPCR过表达FVIII-/-小鼠间未检测到凝血酶生成差异,且流式细胞术和免疫印迹分析显示血小板无可检测的EPCR表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In hemophilia bypass therapy, a platelet-dependent mechanism is believed to be primarily responsible for recombinant factor VIIa (rFVIIa)'s hemostatic effect. rFVIIa may also possibly interact with other cells through its binding to endothelial cell protein C receptor (EPCR) or cell surface phospholipids. OBJECTIVES: We aim to investigate the relative contribution of platelet-dependent and platelet-independent mechanisms in rFVIIa-mediated thrombin generation in hemophilic conditions at the injury site. METHODS: Platelets were depleted in acquired and genetic hemophilia mice using anti-platelet antibodies. The mice were subjected to the saphenous vein injury, and the hemostatic effect of pharmacological concentrations of rFVIIa was evaluated by measuring thrombin generation at the injury site. RESULTS: Administration of anti-mouse CD42 antibodies to mice depleted platelets by more than 95%. As expected, hemophilia mice, compared with wild-type mice, generated only a small fraction of thrombin at the injury site. The depletion of platelets in hemophilia mice further reduced thrombin generation. However, when pharmacological doses of rFVIIa were administered to hemophilia mice, substantial amounts of thrombin were generated even in the platelet-depleted hemophilia mice. No differences in thrombin generation were detected among FVIII-/- , EPCR-deficient FVIII-/- , and EPCR-overexpressing FVIII-/- mice depleted of platelets or not. Evaluation of platelets by flow cytometry as well as immunoblot analysis showed no detectable expression of EPCR. CONCLUSIONS: Our data suggest that pharmacological concentrations of rFVIIa generate thrombin in hemophilia in both platelet-dependent and platelet-independent mechanisms.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Keshava S, Pendurthi UR, Esmon CT, et al. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms. J Thromb Haemost. 2020. PMID: 32359012. doi:10.1111/jth.14881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。